Literature DB >> 29456245

Animal models of monoclonal immunoglobulin-related renal diseases.

Christophe Sirac1, Guillermo A Herrera2, Paul W Sanders3, Vecihi Batuman4, Sebastien Bender1, Maria V Ayala1, Vincent Javaugue1,5, Jiamin Teng2, Elba A Turbat-Herrera2, Michel Cogné1, Guy Touchard5, Nelson Leung6, Frank Bridoux1,5.   

Abstract

The renal deposition of monoclonal immunoglobulins can cause severe renal complications in patients with B cell and plasma cell lymphoproliferative disorders. The overproduction of a structurally unique immunoglobulin can contribute to the abnormal propensity of monoclonal immunoglobulins to aggregate and deposit in specific organs. A wide range of renal diseases can occur in multiple myeloma or monoclonal gammopathy of renal significance, including tubular and glomerular disorders with organized or unorganized immunoglobulin deposits. The development of reliable experimental models is challenging owing to the inherent variability of immunoglobulins and the heterogeneity of the pathologies they produce. However, although imperfect, animal models are invaluable tools to understand the molecular pathogenesis of these diseases, and advances in creating genetically modified animals might provide novel approaches to evaluate innovative therapeutic interventions. We discuss the strategies employed to reproduce human monoclonal immunoglobulin-induced kidney lesions in animal models, and we highlight their advantages and shortcomings. We also discuss how these models have affected the management of these deposition diseases and might do so in the future. Finally, we discuss hypotheses that explain some limitations of the various models, and how these models might improve our understanding of other nephropathies without immunoglobulin involvement that have similar pathogenic mechanisms.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29456245     DOI: 10.1038/nrneph.2018.8

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN: 1759-5061            Impact factor:   28.314


  134 in total

1.  Phagocyte depletion inhibits AA amyloid accumulation in AEF-induced huIL-6 transgenic mice.

Authors:  Stephen J Kennel; Sally Macy; Craig Wooliver; Ying Huang; Tina Richey; Eric Heidel; Jonathan S Wall
Journal:  Amyloid       Date:  2014-01-22       Impact factor: 7.141

2.  The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity.

Authors:  Laura Oliva; Ugo Orfanelli; Massimo Resnati; Andrea Raimondi; Andrea Orsi; Enrico Milan; Giovanni Palladini; Paolo Milani; Fulvia Cerruti; Paolo Cascio; Simona Casarini; Paola Rognoni; Thierry Touvier; Magda Marcatti; Fabio Ciceri; Silvia Mangiacavalli; Alessandro Corso; Giampaolo Merlini; Simone Cenci
Journal:  Blood       Date:  2017-01-27       Impact factor: 22.113

3.  Brief report: heavy-chain deposition disease.

Authors:  P Aucouturier; A A Khamlichi; G Touchard; E Justrabo; M Cogne; B Chauffert; F Martin; J L Preud'homme
Journal:  N Engl J Med       Date:  1993-11-04       Impact factor: 91.245

Review 4.  Monoclonal immunoglobulin deposition disease (Randall type). Relationship with structural abnormalities of immunoglobulin chains.

Authors:  J L Preud'homme; P Aucouturier; G Touchard; L Striker; A A Khamlichi; A Rocca; L Denoroy; M Cogné
Journal:  Kidney Int       Date:  1994-10       Impact factor: 10.612

5.  Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish.

Authors:  Shikha Mishra; Jian Guan; Eva Plovie; David C Seldin; Lawreen H Connors; Giampaolo Merlini; Rodney H Falk; Calum A MacRae; Ronglih Liao
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-04-26       Impact factor: 4.733

6.  Unravelling the immunopathological mechanisms of heavy chain deposition disease with implications for clinical management.

Authors:  Frank Bridoux; Vincent Javaugue; Sébastien Bender; Fannie Leroy; Pierre Aucouturier; Céline Debiais-Delpech; Jean-Michel Goujon; Nathalie Quellard; Amélie Bonaud; Marie Clavel; Patrick Trouillas; Florent Di Meo; Jean-Marc Gombert; Jean-Paul Fermand; Arnaud Jaccard; Michel Cogné; Guy Touchard; Christophe Sirac
Journal:  Kidney Int       Date:  2016-10-20       Impact factor: 10.612

7.  Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts.

Authors:  R Liao; M Jain; P Teller; L H Connors; S Ngoy; M Skinner; R H Falk; C S Apstein
Journal:  Circulation       Date:  2001-10-02       Impact factor: 29.690

8.  Light chain effects on alanine and glucose uptake by renal brush border membranes.

Authors:  V Batuman; M Sastrasinh; S Sastrasinh
Journal:  Kidney Int       Date:  1986-11       Impact factor: 10.612

9.  Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients.

Authors:  G Palladini; P Milani; A Foli; M Vidus Rosin; M Basset; F Lavatelli; M Nuvolone; L Obici; S Perlini; G Merlini
Journal:  Leukemia       Date:  2014-07-25       Impact factor: 11.528

10.  Nephrotoxic potential of Bence Jones proteins.

Authors:  A Solomon; D T Weiss; A A Kattine
Journal:  N Engl J Med       Date:  1991-06-27       Impact factor: 91.245

View more
  9 in total

Review 1.  An update of proliferative glomerulonephritis with monoclonal immunoglobulin deposits.

Authors:  Manna Li; Gaosi Xu
Journal:  Clin Kidney J       Date:  2021-12-14

2.  Monoclonal Gammopathy of Renal Significance with Progression to Multiple Myeloma in a Patient with ASIA-MO Syndrome.

Authors:  David Alejandro Vargas Gutiérrez; Karina Ivonne Arias Callejas; Edwin Pavel Palacios Ruiz; Priscila Joseline Pérez Vinueza; Juan Diego Muñoz Vega; Ana Karen G Mejía Geraldo; Ingrid Salinas Zaldívar
Journal:  Case Rep Hematol       Date:  2022-05-24

3.  Free light chains injure proximal tubule cells through the STAT1/HMGB1/TLR axis.

Authors:  Rohit Upadhyay; Wei-Zhong Ying; Zannatul Nasrin; Hana Safah; Edgar A Jaimes; Wenguang Feng; Paul W Sanders; Vecihi Batuman
Journal:  JCI Insight       Date:  2020-07-23

Review 4.  Kidney injury and disease in patients with haematological malignancies.

Authors:  Frank Bridoux; Paul Cockwell; Ilya Glezerman; Victoria Gutgarts; Jonathan J Hogan; Kenar D Jhaveri; Florent Joly; Samih H Nasr; Deirdre Sawinski; Nelson Leung
Journal:  Nat Rev Nephrol       Date:  2021-03-30       Impact factor: 28.314

5.  Glomerulopathic Light Chain-Mesangial Cell Interactions: Sortilin-Related Receptor (SORL1) and Signaling.

Authors:  Guillermo A Herrera; Luis Del Pozo-Yauner; Jiamin Teng; Chun Zeng; Xinggui Shen; Takahito Moriyama; Veronica Ramirez Alcantara; Bing Liu; Elba A Turbat-Herrera
Journal:  Kidney Int Rep       Date:  2021-03-13

6.  Cellular antioxidant mechanisms control immunoglobulin light chain-mediated proximal tubule injury.

Authors:  Kai Er Ying; Wenguang Feng; Wei-Zhong Ying; Paul W Sanders
Journal:  Free Radic Biol Med       Date:  2021-05-12       Impact factor: 8.101

Review 7.  Extracellular vesicles mediate cellular interactions in renal diseases-Novel views of intercellular communications in the kidney.

Authors:  Ping L Zhang; Ming-Lin Liu
Journal:  J Cell Physiol       Date:  2021-01-11       Impact factor: 6.513

8.  The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.

Authors:  Nelson Leung; Frank Bridoux; Vecihi Batuman; Aristeidis Chaidos; Paul Cockwell; Vivette D D'Agati; Angela Dispenzieri; Fernando C Fervenza; Jean-Paul Fermand; Simon Gibbs; Julian D Gillmore; Guillermo A Herrera; Arnaud Jaccard; Dragan Jevremovic; Efstathios Kastritis; Vishal Kukreti; Robert A Kyle; Helen J Lachmann; Christopher P Larsen; Heinz Ludwig; Glen S Markowitz; Giampaolo Merlini; Peter Mollee; Maria M Picken; Vincent S Rajkumar; Virginie Royal; Paul W Sanders; Sanjeev Sethi; Christopher P Venner; Peter M Voorhees; Ashutosh D Wechalekar; Brendan M Weiss; Samih H Nasr
Journal:  Nat Rev Nephrol       Date:  2019-01       Impact factor: 28.314

9.  Crystalline deposits in the cornea and various areas of the kidney as symptoms of an underlying monoclonal gammopathy: a case report.

Authors:  C Lindemann; P Enders; P T Brinkkoetter; L A Völker
Journal:  BMC Nephrol       Date:  2021-04-06       Impact factor: 2.388

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.